Tag: stock

In accordance with section 30 of the Capital Markets Act, Pandora A/S hereby announces that
BlackRock, Inc. has notified the company that it now holds 7,485,780 shares, corresponding to 9.47% of the total voting rights and share capital (previously 9.51%). Additionally, BlackRock, Inc. controls voting rights attached to financial instruments amounting to 0.50% (previously 0.49%). In total, BlackRock, Inc. control 9.98% of the company’s voting rights (previously 10.01%).

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SkyCrest Capital, a global fintech innovator, today announced the launch of its transformative Pension Plan, a structured asset growth initiative set to begin on Monday, June 23, 2025. Powered by the proprietary SAX-iCore AI Structural Recognition System and executed via the LEXO decentralized trading platform, the plan targets a 150% net return in its first week, offering individual traders and investors a disciplined, AI-driven path to wealth accumulation.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders following a class action complaint that was filed against Maravai on March 3, 2025 with a Class Period from August 7, 2024 and February 24, 2025. Our investigation concerns whether the board of directors of Maravai have breached their fiduciary duties to the company.